Quince Therapeutics, Inc. (QNCX) - Net Assets
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has net assets worth $1.06 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.90 Million) and total liabilities ($108.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Quince Therapeutics, Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.06 Million |
| % of Total Assets | 0.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | -82.5% |
| 10-Year Change | N/A |
| Growth Volatility | 44.33 |
Quince Therapeutics, Inc. - Net Assets Trend (2017–2024)
This chart illustrates how Quince Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Quince Therapeutics, Inc. balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Quince Therapeutics, Inc. (2017–2024)
The table below shows the annual net assets of Quince Therapeutics, Inc. from 2017 to 2024. For live valuation and market cap data, see market cap of Quince Therapeutics, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $30.15 Million | -64.57% |
| 2023-12-31 | $85.08 Million | -15.42% |
| 2022-12-31 | $100.59 Million | -15.17% |
| 2021-12-31 | $118.59 Million | -31.16% |
| 2020-12-31 | $172.26 Million | +49.17% |
| 2019-12-31 | $115.48 Million | +61.69% |
| 2018-12-31 | $71.42 Million | +452.17% |
| 2017-12-31 | $-20.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Quince Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35612300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $44.00K | 0.15% |
| Other Comprehensive Income | $-35.00K | -0.12% |
| Other Components | $406.61 Million | 1348.80% |
| Total Equity | $30.15 Million | 100.00% |
Quince Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Quince Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Strategic Energy Resources Ltd
AU:SER
|
$11.14 Million |
|
Bioatla Inc
NASDAQ:BCAB
|
$11.14 Million |
|
Trainline Plc
LSE:TRN
|
$11.14 Million |
|
elumeo SE
XETRA:ELB
|
$11.14 Million |
|
Sarthak Metals Limited
NSE:SMLT
|
$11.13 Million |
|
Concord Medical Services Holdings
NYSE:CCM
|
$11.12 Million |
|
Patria Private Equity Trust
LSE:PPET
|
$11.12 Million |
|
Walker River Resources Corp.
V:WRR
|
$11.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quince Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 85,084,000 to 30,146,000, a change of -54,938,000 (-64.6%).
- Net loss of 56,828,000 reduced equity.
- Other comprehensive income decreased equity by 3,082,000.
- Other factors increased equity by 4,972,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.83 Million | -188.51% |
| Other Comprehensive Income | $-3.08 Million | -10.22% |
| Other Changes | $4.97 Million | +16.49% |
| Total Change | $- | -64.57% |
Book Value vs Market Value Analysis
This analysis compares Quince Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.94 | $1.33 | x |
| 2018-12-31 | $3.31 | $1.33 | x |
| 2019-12-31 | $6.07 | $1.33 | x |
| 2020-12-31 | $5.90 | $1.33 | x |
| 2021-12-31 | $3.99 | $1.33 | x |
| 2022-12-31 | $3.00 | $1.33 | x |
| 2023-12-31 | $2.28 | $1.33 | x |
| 2024-12-31 | $0.70 | $1.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quince Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -188.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.80x
- Recent ROE (-188.51%) is below the historical average (-55.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.21 Million |
| 2018 | -17.47% | 0.00% | 0.00x | 1.02x | $-19.62 Million |
| 2019 | -32.02% | 0.00% | 0.00x | 1.08x | $-48.53 Million |
| 2020 | -44.61% | 0.00% | 0.00x | 1.10x | $-94.08 Million |
| 2021 | -75.85% | 0.00% | 0.00x | 1.12x | $-101.80 Million |
| 2022 | -51.36% | 0.00% | 0.00x | 1.03x | $-61.72 Million |
| 2023 | -36.89% | 0.00% | 0.00x | 2.12x | $-39.89 Million |
| 2024 | -188.51% | 0.00% | 0.00x | 3.80x | $-59.84 Million |
Industry Comparison
This section compares Quince Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $1.06 Million | 0.00% | 102.78x | $11.14 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mut… Read more